ROSEVILLE, Minn.--(BUSINESS WIRE)--Rebiotix Inc. announces that Ryan Gordon, Ph. D., has joined the organization’s leadership team as vice president of technical operations. Gordon brings more than 14 years of experience in pharmaceutical research and product development, business strategy, technical sales, and leadership to Rebiotix. He is a recognized expert in transdermal drug delivery.
The Roseville, Minn.-based biotechnology company is pioneering a practical and non-antibiotic treatment for recurrent Clostridium difficile infection (CDI) known as Microbiota Restoration Therapy (MRT). CDI has been linked to over 14,000 deaths annually in the US, and has become the most common healthcare-associated infection in some parts of the country, surpassing Methicillin-resistant Staphylococcus aureus (MRSA) infections. There are few evidence-based approaches to the treatment of multiple recurrent CDI.
Studies have shown that fecal transplant, the predecessor to MRT, was highly successful in curing recurrent CDI. However, it involved time-consuming donor screening and unappealing fecal sample preparation processes for the physician. MRT is designed to solve those problems.
In his new role, Gordon will lead the technical operations of the company focusing on the commercialization of its lead treatment for recurrent CDI and the development of its second generation product.
“People suffering from recurrent CDI have no therapeutic options outside of multiple courses of antibiotics,” says Gordon. “I joined Rebiotix because of the opportunity to bring a new therapy to market that could have a profound impact on patients’ lives.”
Most recently, Gordon served as global business manager for 3M’s Drug Delivery Systems Division where he led the organization’s global transdermal components and packaging film OEM business, including management of the commercial and new product pipeline portfolios. Gordon holds a PhD in chemical engineering from the University of Minnesota, Minneapolis, MN, and a BS in chemical engineering from the University of Wisconsin, Madison, WI.
“Ryan brings world-class pharmaceutical product development experience to Rebiotix, along with business strategy, technical sales and leadership of cross-functional teams,” says Rebiotix CEO Lee Jones. “His knowledge, combined with technical and manufacturing experience, will be key in bringing our lead product to market and establishing Rebiotix as the leader in the field of microbiota restoration therapy.”
About Rebiotix
Rebiotix Inc. is a results-oriented
biotechnology company revolutionizing the treatment of challenging
gastrointestinal diseases, such as recurring Clostridium difficile
infection, by harnessing the power of the human microbiome. The
Roseville, Minn.-based company is pioneering practical and
non-antibiotic treatments that reverse pathogenic processes and restore
healthy gut flora through the transplantation of live microorganisms.
For more information, visit www.Rebiotix.com.
